Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access ...
Yahoo Finance5d
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
The WAVE trial was designed to evaluate the efficacy ... The proportion of AVG patients who were free from an adverse event was higher than the safety PG (95.4% vs. 89.0%, p=0.0162).
Merit Medical’s WRAPSODY WAVE trial ‘exceeds performance goals’ for AVG patients
Systems announced six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access Efficacy pivotal ...